ALPHALIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Alphalin, and what generic alternatives are available?
Alphalin is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in ALPHALIN is vitamin a palmitate. There are fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vitamin a palmitate profile page.
Summary for ALPHALIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Patent Applications: | 2,830 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ALPHALIN at DailyMed |
US Patents and Regulatory Information for ALPHALIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | ALPHALIN | vitamin a palmitate | CAPSULE;ORAL | 080883-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |